This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Hang on a second…

This CME Activity has expired and is no longer available for credit.

Monotherapy, Combination Therapy, Triple Therapy: What Is Ideal for Your Type 2 Patients? A 42-Year-Old Woman With T2DM

Monotherapy, Combination Therapy, Triple Therapy: What Is Ideal for Your Type 2 Patients? A 42-Year-Old Woman With T2DM

Format

Patient Case Study

Time to Complete

30 minutes

Released

June 27, 2016

Expires

October 31, 2017
Add to Queue


Maximum Credits

0.50 / AMA PRA Category 1 Credit(s)TM

Accredited Provider



This educational activity is provided by Haymarket Medical Education.

Commercial Supporter

Supported by an educational grant from AstraZeneca

Program Description

An unmet need in type 2 diabetes mellitus (T2DM) management is that few patients achieve established, evidence-based diabetes control targets and treatment goals. Complications from T2DM place a high burden on healthcare resource utilization and costs, rising incrementally with increasing severity of complications. This case study presentation is of a 42-year-old woman with T2DM with multiple comorbidities and increasing beta-cell destruction. It highlights the importance of utilizing a shared decision-making model when adding/removing an agent.

Intended Audience

General internal medicine, internal medicine subspecialties, and other healthcare professionals with an interest in diabetes management

Educational Objectives

At the conclusion of this activity, participants should be better able to:

  • Describe the complex pathophysiology of T2DM, including the defects that contribute to disease progression
  • Review the potential glycemic and extraglycemic benefits of novel and emerging combination treatment strategies for appropriate patients with T2DM
  • Assess the need to initiate or intensify treatment, considering natural disease progression, side effects, glycemic/nonglycemic treatment goals, complications of diabetes, and individual patient needs
  • Implement strategies for more effective patient education/counseling about ongoing self-management, including treatment goals/expectations, adherence, and managing adverse events and comorbidities

Conflict Of Interest Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, HME requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.

Faculty

John E. Anderson, MD (Chair)
TriStar Centennial Medical Center
The Frist Clinic
Nashville, TN

Dr. Anderson is a consultant for Eli Lilly, Boehringer Ingelheim, AstraZeneca, Sanofi, Janssen, and Abbott Diabetes. He is also on the speakers’ bureaus for Eli Lilly, Boehringer Ingelheim, AstraZeneca, Sanofi, and Janssen.

Accredited Provider Disclosure

Haymarket Medical Education staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.

Credit

0.50

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

Haymarket Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.

Disclaimer

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AstraZeneca and Haymarket Medical Education. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

If you have any questions relating to the accreditation of this activity, please contact cmequestions@haymarketmedical.com.

Instructions

To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

Privacy Policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue